Clathrin Nanoparticles for Non-Invasive BDNF Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering brain-derived neurotrophic factor (BDNF) across the blood-brain barrier are invasive, have poor pharmacokinetic profiles, and often increase immunogenicity or toxicity, limiting their effectiveness in treating neurodegenerative and psychiatric disorders.
Innovation Solution
The use of clathrin nanoparticles, specifically clathrin cages or triskelia linked with BDNF via polyethylene glycol conjugation, which act as CNS targeting agents to facilitate non-invasive delivery of BDNF across the nasal barrier, enhancing its stability and penetration into the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BDNF is administered directly into the brain or via invasive methods, then CNS delivery is improved, but the procedure becomes invasive and not suitable for routine clinical practice
Solution Approach 1:
The patent uses nanoparticles as intermediary carriers to deliver BDNF across the blood-brain barrier. These nanoparticles serve as a mediator that can transport the neurotrophic factor into the CNS through the nasal barrier or BBB without requiring invasive procedures, thus resolving the contradiction between reliable CNS delivery and ease of operation.
Solution Approach 2:
The patent replaces invasive mechanical delivery methods (such as direct brain infusion or surgical implantation) with noninvasive nasal administration of nanoparticle-based BDNF formulations. This substitution eliminates the need for complex surgical procedures while maintaining effective CNS delivery.
2Reliability
If BDNF plasma half-life is extended or BBB penetrability is improved, then therapeutic effectiveness is improved, but immunogenicity or toxicity increases
Solution Approach 1:
Nanoparticles serve as protective intermediaries that encapsulate BDNF, allowing the neurotrophic factor to penetrate the BBB and extend its half-life without direct exposure to the immune system. This mediator approach maintains therapeutic effectiveness while reducing immunogenicity and toxicity associated with prolonged BDNF circulation.
Solution Approach 2:
The patent modifies the physical and chemical parameters of BDNF delivery by using nanoparticle carriers with specific size, charge, and surface property characteristics. These parameter changes enable improved BBB penetrability and extended half-life while maintaining biocompatibility and reducing harmful immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves significant and sustained delivery of BDNF to the brain, improving molecular, cellular, and behavioral outcomes, including increased neurogenesis, synaptogenesis, and cognitive enhancement, while minimizing toxicity and immunogenicity.
Implementation Method 1
clathrin nanoparticles, specifically clathrin cages or triskelia linked with BDNF via polyethylene glycol conjugation, which act as CNS targeting agents to facilitate non-invasive delivery of BDNF across the nasal barrier
Data Source
AI summary
Compositions comprising clathrin nanoparticles and methods for treating neurological-associated disorders.